



GIRFT breast pathways

Tracey Irvine

Consultant Oncoplastic Surgeon

Senior Clinical Advisor GIRFT, National Clinical Lead Breast Surgery, CQC Breast Specialty Advisor



GIRFT is part of an aligned set of programmes within NHS England



Breast Surgery

GIRFT Programme National Specialty Report

by Fiona MacNeill, Clinical Lead and Tracey Irvine, Senior Clinical Advisor

February 2021



GIRFT visits



- Almost every unit struggling with volume of referrals
- Having to see patients outside one stop to meet two week targets
- Report data:
 - Over half a million referrals per year
 - Referrals increased 20% in 3 years 42000 to 50000 a month (2015-18)
 - Conversion remained relatively stable at 5%
 - No other possible routes for referral for non urgent symptoms
- Huge variation in performance
- Units developing their own solutions
- Direct access referrals, age specific pathways, mastalgia pathways in report





GIRFT core recommendation

Recommendation	Actions	Owners	Timescale
Core Recommendation 1. Ensure that new breast patient referral and	a Provide primary care support and guidance to allow best use of the access pathway.	Trusts / commissioners / Cancer Alliances	For immediate action
assessment pathways are timely and centred around the individual	b Ensure that access and assessment pathways are evidence-based, risk-adapted and standardised to support safety and cost efficiency.	Trusts / commissioners/ Cancer Alliances	For immediate action
with the aim of providing the best outcomes and experience.	c Redesign and pilot breast clinic access (referral) and assessment pathways to further reduce barriers to early diagnosis, support the Faster Diagnosis Standard and allow patient choice. Ensure new ways of working are audited.	Trusts / commissioners / Cancer Alliances	For immediate action
	d GIRFT to work with specialty associations and Cancer Alliances to identify the workforce requirements associated with pathway redesign.	GIRFT to work with specialty associations and Cancer Alliances	For immediate action
	e Ensure that breast MDTs have a link to a plastic surgeon.	Trusts / commissioners / Cancer Alliances	For immediate action





Best Practice Timed Pathway (BPTP)

Faster diagnostic pathways: Implementing a timed breast cancer diagnostic pathway

Guidance for local health and social care systems. Best practice timed pathways support the ongoing improvement effort to shorten diagnosis pathways, reduce variation, improve patient experience of care, and meet the Faster Diagnosis Standard (FDS). The guidance is intended for NHS organisations and their staff to adopt consistent, system-wide approaches to managing cancer diagnosis pathways and sets out how cancer diagnosis and treatment planning within 28 days can be achieved.

Version 1, 14 July 2023





BPTP Philosophy

- Triage of referrals to protect one stop
- Improve pathway for those who need triple assessment
- Allow development of pathways within FDS for those who do not need intensive imaging assessment
- See the right patient in the right care setting
- Receptor status to be available at diagnosis
- Workforce planning to meet the FDS...





Faster Diagnostic Standard

The new standard is intended to:

- reduce the time between referral and diagnosis of cancer. The timed pathway sets the expectation that a breast cancer diagnosis includes the tumour receptor status, including HER2. Communicating the cancer or non-cancer diagnosis to the patient is required to stop the 28-day clock as specified within the CWT guidance.
- help reduce anxiety for the cohort of people who will be diagnosed with cancer or have cancer ruled out.
- reduce unwarranted variation in England by understanding how long it is taking people to receive a diagnosis or have cancer ruled out.
- represent a significant improvement on the previous two-week wait to first appointment target, and a more person-centred performance standard.

One Stop Clinic (OSC)

One of the benefits of the new standard is optimised referral triage to ensure effective use of limited resources in the one stop breast clinic.

The challenge is to manage all patients referred with breast symptoms appropriately. Those with suspected cancer should be seen in a 'one stop clinic' with same day access to clinical examination, mammography, ultrasound and biopsy.

Non-suspected cancer pathways should maintain close links into OSC services and refer any patients on the pathway that present with red-flag symptoms. Pathways should be developed in line with existing models of care which have already been evaluated, as well as best practice more broadly.



Benefits of pathway change

For systems:

- Effective management of patients who are not suspected to have cancer will reduce demand on imaging and pathology services.
- Improved quality, safety, and effectiveness of care with reduced variation and improvement in outcomes.

For clinicians:

 Access to appropriate pathways that better meet the needs of people referred with breast symptoms where cancer is not suspected, and allow for imaging and pathology resources to be focused on urgent referrals where cancer is suspected.





28-day best practice timed pathway (cancer suspected)

	Day 0	By Day 3	By Day 10	By Day 17	By Day 24	By Day 28	
	Receipt of referral		Local diagnostic centre				
Cancer suspected	Suspected cancer GP referral ¹ Including a minimum dataset ² and physical patient examination. NHS Breast Screening Programme (routine and very high risk patients); or Those on annual survelillace (family history and post-cancer follow up) ³ Day 0 is the decision to recall in NHSBSP or the abnormal mammogram report at the local trust.	by a suitably trained member of the service into suspected cancer OR cancer not suspected pathway (below).	Straight to one-stop clinic for same day Examination, Mammogram, US ^s and biopsy ⁷ (if required). Frailty Assessment carried out.	MDT Discussion ⁹ of diagnosis including immunohistochemis try (ER, PR, HER2) Discuss need for Genetic testing or further imaging if required (e.g. MRI or staging).	MDT Discussion of ISH/FISH (where relevant) and Imaging results (where possible). Results clinic visit; Clinical Review, patier diagnosis of cancer of out, record FDS, comr further tests if required Discuss treatment op Personalised Care and MDT input, optimisatio	or cancer is ruled munication with CNS, I. otions and d Support plan with	
Patient information	Patient information Provided in primary care	Patient informati Provided at Outpatie Appointment (OPA) assessment	d at Outpatient ment (OPA) [®] or clinic				

Key points

Any urgent GP referrals for suspected cancer that are diagnosed as metastatic disease with an unknown primary are still covered by the FDS.

A referral for Breast Screening Assessment would only be made after there is consensus that the patient needs to be assessed, whether this is by the initial two readers or after arbitration.

NB: numbers on the pathway link to the detailed information section of the Breast Cancer Best Practice Timed Pathway Guidance document.



Produced in partnership by GIRFT and the NHS England Cancer programme



Cancer not suspected

The purpose of the 'cancer not suspected' pathways is to reduce unnecessary and inappropriate imaging, to make the most effective use of limited resources.

A number of different models have been suggested and examples can be found in the GIRFT Breast Surgery National Specialty Report. Any new models need robust evaluation to ensure they meet the needs of patients. The Association of Breast Surgery (ABS) are developing a platform to support the evaluation of breast pain pathways (see link below).

Patient experience of care

One of the benefits of the pathway for patients is care and support that meets the needs of those in whom breast cancer is not suspected but are experiencing significant issues with their breasts, using evidence based clinically robust models of care delivery and subject to evaluation.

See <u>ABS position statement</u> on Breast Pain.

Cancer Alliances should ensure that any pathways set up to manage patients with breast pain, gynaecomastia and other non-suspected cancer referrals meet the needs of those patients and are delivered in the most clinically appropriate setting.

Conversion rates

For England in 2020/21 the percentage of urgent breast referrals which resulted in a diagnosis of cancer was as follows:


- 5.7% for TWR/urgent breast cancer referrals
- 1.3% for breast symptomatic referrals

This was in comparison to a national rate of 7% for all tumour sites during the same period.

The lower conversion rate for referrals for breast symptoms shows that triage is effective.



Resources



Produced in partnership by GIRFT and the NHS England Cancer programme



28-day best practice timed pathway (cancer not suspected)

	Day 0	By Day 3	By Day 14	By Day 28	
	Receipt of referral		Local diagnostic c	If cancer is suspected, refer straight to one-stop clinic /	
Cancer not suspected	Breast symptomatic referral ⁴ e.g. Gynaecomastia (according to ABS/RCGP <u>Guidelines</u>), Asymptomatic, Breast pain ¹¹ , Implant problem / infection	Clinical triage ⁵ by a suitably trained member of the service into suspected cancer (above) OR cancer not suspected pathway	 Assessment in an appropriate setting (i.e. Bespoke Breast pain ¹¹ or surgical follow up clinic). New pathways must be subject to routine data collection and evaluation. For most patients informed cancer is ruled out at first visit and record FDS. 	 Results clinic visit if appropriate; Clinical Review, patient informed of diagnosis of cancer or cancer is ruled out, record FDS, communication with CNS, further tests if required. Discuss treatment options and Personalised Care and Support plan with MDT input, optimisation and support. 	MDT on same day (parallel clinic) or next available. These patients should still receive their cancer diagnosis as per FDS, by Day 28. Clinical triage Clinical triage can be done by a suitably trained member of the service. People who
Patient Information	Patient information Provided in primary care ¹	Patient information Provided at Outpatient Appointment (OPA) ⁸ or clinic assessment	Cancer likely, communication a record FDS when person is inform OR Cancer is ruled out. ⁸ Personalised care and support sh	attend an outpatient appointment should, if possible, have same day investigations to reduce repeat visits and improve experience.	

NB: numbers on the pathway link to the detailed information section of the Breast Cancer Best Practice Timed Pathway Guidance document.



Produced in partnership by GIRFT and the NHS England Cancer programme

Resources

<u>https://associationofbreastsurgery.org.uk/professionals/audit/getting-it-right-first-time-girft/</u>

www.gettingitrightfirsttime.co.uk

https://future.nhs.uk/system/login?nextURL=%2Fconnect%2Eti%2Fcanc%2Fv iew%3FobjectId%3D164174853

<u>https://www.england.nhs.uk/publication/rapid-cancer-diagnostic-and-assessment-pathways/</u> <u>https://gettingitrightfirsttime.co.uk/wp-</u> <u>content/uploads/2023/10/BestPracticeTimedDiagnosticCancerPathwaysSum</u> <u>mary-Guide-FINAL-V2-Oct-23-1.pdf</u>